모든 카테고리
| Product Name | 기술 | Action |
|---|---|---|
| 세톡시마브, 에르비투크스, EGFR, IMC- C225, 항 EGFR 일종 항체, 히메릭 IgG1 항체, 종양 생물학 / 대장암 항체 / 머리 및 목 암 항체, CAS 번호 205923-56-4 | Trade Name : Erbitux Target : EGFR Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 650(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| 아플리버셉트 | Trade Name : Eylea Target : VEGF/PlGF Molecular Type : Fusion Protein Sales in 2025 (Millions of USD) : 7770(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| 트라스투주맙 엠탄신 ,캐실라 ,HER2 ,T-DM1 ,아도-트라스투주맙 엠탄신 ,HER2 표적 ADC ,미세소관 억제제 접합체 ,분해되지 않는 링커 ADC ,마이탄시노이드 ADC ,2세대 ADC | Trade Name : Kadcyla Target : Her2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 2000~2200(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| 트라스투주맙 데룩스테칸 | Trade Name : Enhertu Target : Her2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 4500~5000(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| 트라스투주맙 | Trade Name : Herceptin Target : Her2 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 3000 All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| 니볼루마브와 베라히알루로니다제 알파-PMPH,오프디보 SC,오프디보 주사,오프디보 Qvantig,BMS-986251,하위 PD-1 억제기,통합제품 (901 및 932) | Trade Name : Opdivo Qvantig® Target : N/A Molecular Type : Combination Product (901 and 932) Sales in 2025 (Millions of USD) : N/A All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| 니볼루마브와 관련한 니볼루마브-rmbw, Opdualag 주입, PD-1, LAG-3, BMS-986213, PD-1 / LAG-3 이중 억제기, 고정 복용량 복합 면역 치료, 고정 복용량 복합 (902 및 962) | Trade Name : Opdualag Target : PD-1, LAG-3 Molecular Type : Fixed-dose Combination (902 and 962) Sales in 2025 (Millions of USD) : 1000~1200(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get ... |
|
| 니볼루마브, 옵디보, PD-1, BMS-936558, ONO-4538, 안티-PD-1, 면역 체크 포인트 억제기, 일종 항체, CAS 번호 946414-94-4 | Trade Name : Opdivo Target : PD-1 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 12000 All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
